Skip to main content
OpenTrials
Completed

NCT Number: NCT02853188

Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung

The aim of the study is to evaluate if the plasma activity of the tissue factor at the time of the diagnosis of a lung cancer, before any treatment, or after the treatment of induction (surgery or two first cures of chemotherapy), can be a predictive factor of venous thromboembolism disease in the year which follows the diagnosis, independently of the other parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer of Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre hospitalier intercommunal de Créteil, Créteil, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of more than 18 years old
  • Patients with cancer of lung diagnosis carried for less than 2 months and which were not handled yet, either by surgery or by chemotherapy, or by radiotherapy
  • Patients whose life expectancy is considered 3-month-old a superior
  • Patients having given writed consent
  • Patients affiliated to a national insurance scheme or benefiting from such a diet
  • Patients having received a treatment (processing) anticoagulating in preventive dose if this treatment was stopped at least 3 days before the 1st taking or patients not receiving an anticoagulating treatment (in case of curative treatment, the latter was before arrested at least 3 months

Exclusion criteria

  • Patients having a hepatic disease with coagulation disorders
  • Patients under anticoagulants with dose guardian in 3 months preceding the study or presenting an active infection
  • Patients having a history of other cancer considered as cured and diagnosed for less than 5 years (with the exception of the patients operated for an in situ carcinoma of the neck of the womb or the patients having undergone the excision of a squamous-cell carcinoma)

Treatment and study plan

venous thromboembolism

Other

Primary outcomes

  1. Venous thromboembolism occurence

    Time frame: 2 years

  2. Tissue factor

    Time frame: 2 years

    Tissue factor is measured by kinetic-chromogenic assay

Sponsors and collaborators

Lead sponsor

Hopital Foch

Other

Registry information

Official study title

Does the Measure of the Plasma Tissue Factor Allow to Predict a Venous Thromboembolism Episode for Patients Presenting a Primitive Lung Cancer?

Acronym: FT-KBP

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Aug 2, 2016
Registry last updated
Aug 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.